CDKN2A and cancer: Leveraging circulating DNA from 6030 patients with various cancer types, Jee et al. found several genes to be significantly associated with an increased VTE risk independent of cancer type and cancer type specific mutations, including KRAS (adjusted HR 1.65), EGFR (adjusted HR 1.62), CDKN2A (adjusted HR 1.84), KEAP1 (adjusted HR 2.50), STK11 (adjusted HR 1.61), CTNNB1 (adjusted HR 2.70), TP53 (adjusted HR 1.85), and ERBB2 (adjusted HR1.72) [56▪▪].